Table 1.
Heart rates in mice during in vivo experiments
| Reperfusion |
|||||
|---|---|---|---|---|---|
| Experimental Group | Baseline | Occlusion | 30 min | 60 min | 120 min |
| Control | 407 ± 15 | 420 ± 11 | 418 ± 10 | 416 ± 12 | 404 ± 11 |
| AHG | 401 ± 14 | 410 ± 12 | 411 ± 12 | 412 ± 12 | 419 ± 13 |
| APC | 413 ± 17 | 383 ± 27 | 424 ± 19 | 417 ± 14 | 431 ± 15 |
| D-4F | 402 ± 8 | 387 ± 11 | 419 ± 11 | 404 ± 10 | 402 ± 14 |
| AHG + APC | 434 ± 22 | 407 ± 10 | 415 ± 12 | 424 ± 13 | 438 ± 13 |
| D-4F (0.12 mg/kg) + AHG + APC | 420 ± 12 | 412 ± 15 | 405 ± 19 | 433 ± 10 | 417 ± 13 |
| D-4F (0.6 mg/kg) + AHG + APC | 429 ± 15 | 408 ± 18 | 398 ± 14 | 389 ± 11 | 399 ± 10 |
| l-NAME | 388 ± 12 | 386 ± 9 | 398 ± 13 | 394 ± 12 | 392 ± 12 |
| D-4F (0.6 mg/kg) + l-NAME + AHG + APC | 422 ± 16 | 420 ± 18 | 427 ± 18 | 414 ± 15 | 418 ± 16 |
Data are means ± SE (in beats/min). AHG, acute hyperglycemia; APC, anesthetic preconditioning; D-4F, Ac-DWFKAFYDKVAEKFKEAF-NH2 (apolipoprotein A-I mimetic); l-NAME, NG-nitro-l-arginine methyl ester (nitric oxide synthase inhibitor).